Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone Approved to Launch Novel GIST Treatment in China

publication date: Mar 31, 2021

CStone Pharma of Suzhou was approved to launch Ayvakit (avapritinib) tablets, a treatment for unresectable/metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation. The NMPA approval of Ayvakit was based on an open-label Phase I/II bridging study in China patients with advanced GIST. All eight patients showed anti-tumor activity. One week ago, CStone announced China approval of a RET inhibitor for RET non-small cell lung cancer. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here